|
1
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Almatroudi A: The incidence rate of
colorectal cancer in Saudi Arabia: An observational descriptive
epidemiological analysis. Int J Gen Med. 13:977–990. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kanani A, Veen T and Søreide K:
Neoadjuvant immunotherapy in primary and metastatic colorectal
cancer. Br J Surg. 108:1417–1425. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Goc J, Lv M, Bessman NJ, Flamar AL, Sahota
S, Suzuki H, Teng F, Putzel GG; JRI Live Cell Bank; Eberl G, ; et
al: Dysregulation of ILC3s unleashes progression and immunotherapy
resistance in colon cancer. Cell. 184:5015–5030.e16. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Jiang Y, Huo Z, Qi X, Zuo T and Wu Z:
Copper-induced tumor cell death mechanisms and antitumor
theragnostic applications of copper complexes. Nanomedicine (Lond).
17:303–324. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lelièvre P, Sancey L, Coll JL, Deniaud A
and Busser B: The multifaceted roles of copper in cancer: A trace
metal element with dysregulated metabolism, but also a target or a
bullet for therapy. Cancers (Basel). 12:35942020. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
da Silva DA, De Luca A, Squitti R,
Rongioletti M, Rossi L, Machado CML and Cerchiaro G: Copper in
tumors and the use of copper-based compounds in cancer treatment. J
Inorg Biochem. 226:1116342022. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
De Luca A, Barile A, Arciello M and Rossi
L: Copper homeostasis as target of both consolidated and innovative
strategies of anti-tumor therapy. J Trace Elem Med Biol.
55:204–213. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tsvetkov P, Coy S, Petrova B, Dreishpoon
M, Verma A, Abdusamad M, Rossen J, Joesch-Cohen L, Humeidi R,
Spangler RD, et al: Copper induces cell death by targeting
lipoylated TCA cycle proteins. Science. 375:1254–1261. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yang S, He X, Zhao J, Wang D, Guo S, Gao
T, Wang G, Jin C, Yan Z, Wang N, et al: Mitochondrial transcription
factor A plays opposite roles in the initiation and progression of
colitis-associated cancer. Cancer Commun (Lond). 41:695–714. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Baszuk P, Marciniak W, Derkacz R,
Jakubowska A, Cybulski C, Gronwald J, Dębniak T, Huzarski T,
Białkowska K, Pietrzak S, et al: Blood copper levels and the
occurrence of colorectal cancer in Poland. Biomedicines.
9:16282021. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lutsenko S: Dynamic and cell-specific
transport networks for intracellular copper ions. J Cell Sci.
134:jcs2405232021. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Baldari S, Di Rocco G, Heffern MC, Su TA,
Chang CJ and Toietta G: Effects of copper chelation on
BRAFV600E positive colon carcinoma cells. Cancers
(Basel). 11:6592019. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Cui L, Gouw AM, LaGory EL, Guo S,
Attarwala N, Tang Y, Qi J, Chen YS, Gao Z, Casey KM, et al:
Mitochondrial copper depletion suppresses triple-negative breast
cancer in mice. Nat Biotechnol. 39:357–367. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Davis CI, Gu X, Kiefer RM, Ralle M, Gade
TP and Brady DC: Altered copper homeostasis underlies sensitivity
of hepatocellular carcinoma to copper chelation. Metallomics.
12:1995–2008. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhao S, Ye Z and Stanton R: Misuse of RPKM
or TPM normalization when comparing across samples and sequencing
protocols. RNA. 26:903–909. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Conesa A, Madrigal P, Tarazona S,
Gomez-Cabrero D, Cervera A, McPherson A, Szcześniak MW, Gaffney DJ,
Elo LL, Zhang X and Mortazavi A: A survey of best practices for
RNA-seq data analysis. Genome Biol. 17:132016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Gautier L, Cope L, Bolstad BM and Irizarry
RA: affy-analysis of Affymetrix GeneChip data at the probe level.
Bioinformatics. 20:307–315. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Song W, Ren J, Xiang R, Kong C and Fu T:
Identification of pyroptosis-related subtypes, the development of a
prognosis model, and characterization of tumor microenvironment
infiltration in colorectal cancer. Oncoimmunology. 10:19876362021.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sturm G, Finotello F, Petitprez F, Zhang
JD, Baumbach J, Fridman WH, List M and Aneichyk T: Comprehensive
evaluation of transcriptome-based cell-type quantification methods
for immuno-oncology. Bioinformatics. 35:i436–i445. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sui Z, Wu X, Du L, Wang H, Yuan L, Zhang
JV and Yu Z: Characterization of the immune cell infiltration
landscape in esophageal squamous cell carcinoma. Front Oncol.
12:8793262022. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Iasonos A, Schrag D, Raj GV and Panageas
KS: How to build and interpret a nomogram for cancer prognosis. J
Clin Oncol. 26:1364–1370. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sebestyén E, Singh B, Miñana B, Pagès A,
Mateo F, Pujana MA, Valcárcel J and Eyras E: Large-scale analysis
of genome and transcriptome alterations in multiple tumors unveils
novel cancer-relevant splicing networks. Genome Res. 26:732–744.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Koch A, Joosten SC, Feng Z, de Ruijter TC,
Draht MX, Melotte V, Smits KM, Veeck J, Herman JG, Van Neste L, et
al: Analysis of DNA methylation in cancer: Location revisited. Nat
Rev Clin Oncol. 15:459–466. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lambert SA, Jolma A, Campitelli LF, Das
PK, Yin Y, Albu M, Chen X, Taipale J, Hughes TR and Weirauch MT:
The human transcription factors. Cell. 172:650–665. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Xu J, Dai S, Yuan Y, Xiao Q and Ding K: A
prognostic model for colon cancer patients based on eight signature
autophagy genes. Front Cell Dev Biol. 8:6021742020. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kang N, Xie X, Zhou X, Wang Y, Chen S, Qi
R, Liu T and Jiang H: Identification and validation of
EMT-immune-related prognostic biomarkers CDKN2A, CMTM8 and ILK in
colon cancer. BMC Gastroenterol. 22:1902022. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lv H, Liu X, Zeng X, Liu Y, Zhang C, Zhang
Q and Xu J: Comprehensive analysis of cuproptosis-related genes in
immune infiltration and prognosis in Melanoma. Front Pharmacol.
13:9300412022. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhang C, Cheng W, Ren X, Wang Z, Liu X, Li
G, Han S, Jiang T and Wu A: Tumor purity as an underlying key
factor in glioma. Clin Cancer Res. 23:6279–6291. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Mao Y, Feng Q, Zheng P, Yang L, Liu T, Xu
Y, Zhu D, Chang W, Ji M, Ren L, et al: Low tumor purity is
associated with poor prognosis, heavy mutation burden, and intense
immune phenotype in colon cancer. Cancer Manag Res. 10:3569–3577.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Havel JJ, Chowell D and Chan TA: The
evolving landscape of biomarkers for checkpoint inhibitor
immunotherapy. Nat Rev Cancer. 19:133–150. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Turley SJ, Cremasco V and Astarita JL:
Immunological hallmarks of stromal cells in the tumour
microenvironment. Nat Rev Immunol. 15:669–682. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ma R, Yuan D, Guo Y, Yan R and Li K:
Immune effects of γδ T cells in colorectal cancer: A review. Front
Immunol. 11:16002020. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kuwahara T, Hazama S, Suzuki N, Yoshida S,
Tomochika S, Nakagami Y, Matsui H, Shindo Y, Kanekiyo S, Tokumitsu
Y, et al: Intratumoural-infiltrating CD4 + and FOXP3 + T cells as
strong positive predictive markers for the prognosis of resectable
colorectal cancer. Br J Cancer. 121:659–665. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Governa V, Trella E, Mele V, Tornillo L,
Amicarella F, Cremonesi E, Muraro MG, Xu H, Droeser R, Däster SR,
et al: The Interplay Between neutrophils and CD8+ T
cells improves survival in human colorectal cancer. Clin Cancer
Res. 23:3847–3858. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhang L, Yu X, Zheng L, Zhang Y, Li Y,
Fang Q, Gao R, Kang B, Zhang Q, Huang JY, et al: Lineage tracking
reveals dynamic relationships of T cells in colorectal cancer.
Nature. 564:268–272. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Tanaka A and Sakaguchi S: Regulatory T
cells in cancer immunotherapy. Cell Res. 27:109–118. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Pan Y, Yu Y, Wang X and Zhang T:
Tumor-associated macrophages in tumor immunity. Front Immunol.
11:5830842020. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Sousa S, Brion R, Lintunen M, Kronqvist P,
Sandholm J, Mönkkönen J, Kellokumpu-Lehtinen PL, Lauttia S,
Tynninen O, Joensuu H, et al: Human breast cancer cells educate
macrophages toward the M2 activation status. Breast Cancer Res.
17:1012015. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Liang JY, Wang DS, Lin HC, Chen XX, Yang
H, Zheng Y and Li YH: A novel ferroptosis-related gene signature
for overall survival prediction in patients with hepatocellular
carcinoma. Int J Biol Sci. 16:2430–2441. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Helmink BA, Reddy SM, Gao J, Zhang S,
Basar R, Thakur R, Yizhak K, Sade-Feldman M, Blando J, Han G, et
al: B cells and tertiary lymphoid structures promote immunotherapy
response. Nature. 577:549–555. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Petitprez F, de Reyniès A, Keung EZ, Chen
TW, Sun CM, Calderaro J, Jeng YM, Hsiao LP, Lacroix L, Bougoüin A,
et al: B cells are associated with survival and immunotherapy
response in sarcoma. Nature. 577:556–560. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Berntsson J, Nodin B, Eberhard J, Micke P
and Jirström K: Prognostic impact of tumour-infiltrating B cells
and plasma cells in colorectal cancer. Int J Cancer. 139:1129–1139.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Meshcheryakova A, Tamandl D, Bajna E,
Stift J, Mittlboeck M, Svoboda M, Heiden D, Stremitzer S,
Jensen-Jarolim E, Grünberger T, et al: B cells and ectopic
follicular structures: Novel players in anti-tumor programming with
prognostic power for patients with metastatic colorectal cancer.
PLoS One. 9:e990082014. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Lee YJ, Lee HJ, Choi SH, Jin YB, An HJ,
Kang JH, Yoon SS and Lee YS: Soluble HSPB1 regulates VEGF-mediated
angiogenesis through their direct interaction. Angiogenesis.
15:229–242. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Hung CS, Huang CY, Hsu YW, Makondi PT,
Chang WC, Chang YJ, Wang JY and Wei PL: HSPB1 rs2070804
polymorphism is associated with the depth of primary tumor. J Cell
Biochem. 121:63–69. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Cui Z, Sun G, Bhandari R, Lu J, Zhang M,
Bhandari R, Sun F, Liu Z and Zhao S: Comprehensive analysis of
glycolysis-related genes for prognosis, immune features, and
candidate drug development in colon cancer. Front Cell Dev Biol.
9:6843222021. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Herath NI, Spanevello MD, Doecke JD, Smith
FM, Pouponnot C and Boyd AW: Complex expression patterns of Eph
receptor tyrosine kinases and their ephrin ligands in colorectal
carcinogenesis. Eur J Cancer. 48:753–762. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Cho HS, Toyokawa G, Daigo Y, Hayami S,
Masuda K, Ikawa N, Yamane Y, Maejima K, Tsunoda T, Field HI, et al:
The JmjC domain-containing histone demethylase KDM3A is a positive
regulator of the G1/S transition in cancer cells via
transcriptional regulation of the HOXA1 gene. Int J Cancer.
131:E179–E189. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Wang Y, Zhang H, Liu C, Wang Z, Wu W,
Zhang N, Zhang L, Hu J, Luo P, Zhang J, et al: Immune checkpoint
modulators in cancer immunotherapy: Recent advances and emerging
concepts. J Hematol Oncol. 15:1112022. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Bagchi S, Yuan R and Engleman EG: Immune
checkpoint inhibitors for the treatment of cancer: Clinical impact
and mechanisms of response and resistance. Annu Rev Pathol.
16:223–249. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Marin-Acevedo JA, Dholaria B, Soyano AE,
Knutson KL, Chumsri S and Lou Y: Next generation of immune
checkpoint therapy in cancer: New developments and challenges. J
Hematol Oncol. 11:392018. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Roudko V, Cimen Bozkus C, Greenbaum B,
Lucas A, Samstein R and Bhardwaj N: Lynch syndrome and MSI-H
cancers: From mechanisms to ‘off-the-shelf’ cancer vaccines. Front
Immunol. 12:7578042021. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Llosa NJ, Cruise M, Tam A, Wicks EC,
Hechenbleikner EM, Taube JM, Blosser RL, Fan H, Wang H, Luber BS,
et al: The vigorous immune microenvironment of microsatellite
instable colon cancer is balanced by multiple counter-inhibitory
checkpoints. Cancer Discov. 5:43–51. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Ieranò C, Righelli D, D'Alterio C,
Napolitano M, Portella L, Rea G, Auletta F, Santagata S, Trotta AM,
Guardascione G, et al: In PD-1+ human colon cancer cells NIVOLUMAB
promotes survival and could protect tumor cells from conventional
therapies. J Immunother Cancer. 10:e0040322022. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Gao W, Huang Z, Duan J, Nice EC, Lin J and
Huang C: Elesclomol induces copper-dependent ferroptosis in
colorectal cancer cells via degradation of ATP7A. Mol Oncol.
15:3527–3544. 2021. View Article : Google Scholar : PubMed/NCBI
|
